MARKET

KYTX

KYTX

Kyverna Therapeutics
NASDAQ
8.28
+0.26
+3.23%
Opening 12:32 08/12 EDT
OPEN
7.92
PREV CLOSE
8.02
HIGH
8.66
LOW
7.79
VOLUME
520.91K
TURNOVER
--
52 WEEK HIGH
13.67
52 WEEK LOW
2.800
MARKET CAP
503.33M
P/E (TTM)
-2.5247
1D
5D
1M
3M
1Y
5Y
1D
Morgan Stanley Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX)
TipRanks · 4h ago
Kyverna Therapeutics: Buy Rating Reiterated as Pipeline Progress and Strong Financial Runway Support Unchanged $25 Price Target
TipRanks · 6h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (OtherTCHBF), Kyverna Therapeutics, Inc. (KYTX) and Pliant Therapeutics (PLRX)
TipRanks · 7h ago
Kyverna Therapeutics GAAP EPS of -$0.63 beats by $0.05
Seeking Alpha · 20h ago
*Kyverna Therapeutics Reiterates Operating Runway Into 2028 >KYTX
Dow Jones · 20h ago
Press Release: Kyverna Therapeutics Reports -2-
Dow Jones · 20h ago
Press Release: Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Dow Jones · 20h ago
Weekly Report: what happened at KYTX last week (0803-0807)?
Weekly Report · 2d ago
More
About KYTX
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Webull offers Kyverna Therapeutics Inc stock information, including NASDAQ: KYTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYTX stock methods without spending real money on the virtual paper trading platform.